An Analysis of Diabetes Control in Puerto Rico
Project: An analysis of Diabetes Control in Puerto Rico Hypothesis: This project seeks to determine the causes for: i) poor adherence to prescribed treatment by patients, ii) low compliance by providers with national guidelines iii) barriers impose by health insurance in control of diabetes mellitus iv) effectiveness of a disease management program for treatment adherence by patients.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||An Analysis of Variables That Affect Quality of Diabetes Control in Puerto Rico|
|Study Start Date:||March 2010|
|Estimated Study Completion Date:||February 2013|
|Estimated Primary Completion Date:||November 2010 (Final data collection date for primary outcome measure)|
Method (s) The study will consist of three phases:
i) assessment phase,
ii) multimedia health education campaign for patients, providers and local health insurances for adherence improvement
iii) reassessment phase.
Phase I: 600 Hispanic, male and female, residents of Puerto Rico with a diagnosis of type 1 and 2 diabetes mellitus older than 18 of age.
Phase II: 600 patients identified in phase I with individualize health education interventions on the importance of adherence to prescribed medical treatment. 2) Spanish speaking population of Puerto Rico, health service providers, and health insurance companies through a multimedia health education campaign.
Phase III: reassessment of the 600 patients of Phase I.
Data Collection Tools:
i) Demographic information will be obtained by an interview questionnaire. Patients will be assigned a control number automatically by the data system.
ii) Laboratory blood samples for A1C, lipids (total cholesterol, triglycerides and HDL cholesterol), and serum creatinine.
iii) A comprehensive educational adherence program with different media strategies such as: radio spots, newspaper articles, public service announcements, telemedicine services.
Data Analysis: Data will be analyzed using SPSS for Windows.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01117831
|Principal Investigator:||Efrain Rodriguez-Vigil, MD||Center for Diabetes Control, Inc.|